Literature DB >> 25647074

Radiopharmaceuticals as probes to characterize tumour tissue.

Israt S Alam1, Mubarik A Arshad, Quang-Dé Nguyen, Eric O Aboagye.   

Abstract

Tumour cells exhibit several properties that allow them to grow and divide. A number of these properties are detectable by nuclear imaging methods. We discuss crucial tumour properties that can be described by current radioprobe technologies, further discuss areas of emerging radioprobe development, and finally articulate need areas that our field should aspire to develop. The review focuses largely on positron emission tomography and draws upon the seminal 'Hallmarks of Cancer' review article by Hanahan and Weinberg in 2011 placing into context the present and future roles of radiotracer imaging in characterizing tumours.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25647074     DOI: 10.1007/s00259-014-2984-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  214 in total

1.  3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?

Authors:  David C P Cobben; Piet L Jager; Philip H Elsinga; Bram Maas; Albert J H Suurmeijer; Harald J Hoekstra
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

2.  Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Authors:  Masato Shiiba; Keiichi Ishihara; Go Kimura; Tomoyuki Kuwako; Hisashi Yoshihara; Naohisa Yoshihara; Hidetaka Sato; Yukihiro Kondo; Shin-ichi Tsuchiya; Shin-ichiro Kumita
Journal:  Ann Nucl Med       Date:  2011-11-09       Impact factor: 2.668

3.  18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

Authors:  Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

4.  131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.

Authors:  A H Brouwers; U Dorr; O Lang; O C Boerman; W J G Oyen; M G Steffens; E Oosterwijk; H G Mergenthaler; H Bihl; F H M Corstens
Journal:  Nucl Med Commun       Date:  2002-03       Impact factor: 1.690

5.  Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry.

Authors:  Ly-Binh-An Tran; Anne Bol; Daniel Labar; Bénédicte Jordan; Julie Magat; Lionel Mignion; Vincent Grégoire; Bernard Gallez
Journal:  Radiother Oncol       Date:  2012-06-06       Impact factor: 6.280

6.  Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-annexin A5.

Authors:  H H Boersma; I H Liem; G J Kemerink; P W L Thimister; L Hofstra; L M L Stolk; W L van Heerde; M-T W Pakbiers; D Janssen; A J Beysens; C P M Reutelingsperger; G A K Heidendal
Journal:  Br J Radiol       Date:  2003-08       Impact factor: 3.039

7.  Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.

Authors:  Chaan S Ng; Yoshihisa Kodama; Nizar A Mullani; Bruce J Barron; Wei Wei; Roy S Herbst; James L Abbruzzese; Chusilp Charnsangavej
Journal:  J Comput Assist Tomogr       Date:  2009 May-Jun       Impact factor: 1.826

8.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

9.  18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

Authors:  Cristina Nanni; Riccardo Schiavina; Eugenio Brunocilla; Marco Borghesi; Valentina Ambrosini; Lucia Zanoni; Giorgio Gentile; Valerio Vagnoni; Daniele Romagnoli; Giuseppe Martorana; Stefano Fanti
Journal:  Clin Genitourin Cancer       Date:  2013-10-14       Impact factor: 2.872

10.  Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline.

Authors:  Graham Smith; Yongjun Zhao; Julius Leyton; Bo Shan; Quang-de Nguyen; Meg Perumal; David Turton; Erik Årstad; Sajinder K Luthra; Edward G Robins; Eric O Aboagye
Journal:  Nucl Med Biol       Date:  2010-09-01       Impact factor: 2.408

View more
  3 in total

Review 1.  Immuno-PET for Clinical Theranostic Approaches.

Authors:  Clément Bailly; Pierre-François Cléry; Alain Faivre-Chauvet; Mickael Bourgeois; François Guérard; Ferid Haddad; Jacques Barbet; Michel Chérel; Françoise Kraeber-Bodéré; Thomas Carlier; Caroline Bodet-Milin
Journal:  Int J Mol Sci       Date:  2016-12-28       Impact factor: 5.923

Review 2.  Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.

Authors:  Martin Pool; H Rudolf de Boer; Marjolijn N Lub-de Hooge; Marcel A T M van Vugt; Elisabeth G E de Vries
Journal:  Theranostics       Date:  2017-05-27       Impact factor: 11.556

3.  [18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment.

Authors:  Matthew J Oborski; Charles M Laymon; Frank S Lieberman; Yongxian Qian; Jan Drappatz; James M Mountz
Journal:  Tomography       Date:  2016-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.